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INTRODUCTION
In a variety of neoplastic diseases, the presence of circulating tumor cells (CTCs) as well as minimal residual disease in bone marrow gained considerable attention as a prognostic and potentially predictive marker and also as a peculiar feature of tumor biology. Recently, the presence of CTCs has been included as a new item into the international tumor staging systems for several carcinomas, but not yet for melanoma (Singletary et al., 2003; Harris et al., 2007) .
Detection of circulating melanoma cells (CMCs) with reverse transcriptase PCR in peripheral blood has been explored by several investigators, including our own group, over the past 15 years and has been proposed to identify patients with a high risk for relapse or poor outcome in cutaneous as well as uveal melanomas (Mocellin et al., 2006) . Unfortunately, the PCR assay did not show strong predictive information for adjuvant interferon treatment (Fusi et al., 2009 ). An alternative approach for detection of CTCs consists of immunomagnetic cell selection methods for enriching CTC populations followed by flow cytometry or immunohistochemistry for visualization and quantification. Recent advances include the development of an automated immunomagnetic enrichment and staining system (Cell Search; Veridex LLC), which has been approved by the US Food and Drug Administration, allowing its use as an aid for monitoring breast cancer (Riethdorf et al., 2007) , colorectal cancer (Cohen et al., 2008) and prostatic cancer (de Bono et al., 2008) . The system is intended for enumeration of CTCs of epithelial origin defined as CD45 negative, cytokeratins 8, 18, and/or 19 positive after enrichment by means of ferromagnetic beads against the epithelial marker EpCam. Up to now, a method for detection of CMCs has not been validated.
To our knowledge, only two studies addressed the possible impact of the number of enriched CMCs on prognosis. In a prospective study by Ulmer et al., 50 ml blood samples were drawn from 164 patients affected by cutaneous melanoma (29 stage I, 30 stage II, 42 stage III, 63 stage IV). CMCs were enriched by immunomagnetic cell sorting using a murine monoclonal antibody against the melanoma-associated chondroitin sulfate proteoglycan. Positivity for immunomagnetic melanoma cell enrichment correlated with the presence of detectable tumor, and detection of more than one melanoma cell in stage III or IV patients was associated with a significantly decreased overall survival (Ulmer et al., 2004) . On the contrary, another study from the same group showed no significant difference between number of melanoma cells and established prognostic parameters in a cohort of patients affected by primary uveal melanoma (Suesskind et al., 2009 ). The latter work included blood samples examined in a previous study in which a correlation between CMCs and prognostic parameters was found (Ulmer et al., 2008) .
The current understanding of the biological properties of CTCs is very limited. It is in fact totally unclear, whether CTCs are a fraction of cells transiently present in the blood stream as a prerequisite to potentially seed haematogenous metastases of the disease, or represent a unique subpopulation of tumor cells able to survive and circulate in the bloodstream for an extended duration, perhaps with the potential to eventually home to peripheral tissues, where they may or may not be able to initiate formation of metastases.
One report indicated that CTCs might be genomically heterogeneous, even in early disease stages, but that study mainly focused on disseminated tumor cells in bone marrow and lymph nodes, rather than on circulating cells in peripheral blood (Klein et al., 2009) . Tewes et al. (2009) analyzed the molecular profile of CTCs in blood of metastatic breast cancer patients and showed that the profile may provide powerful prognostic information with regard to risk assessment for recurrence and prediction of the efficacy of a given treatment regimen.
It has recently been postulated that there may be a subset of cells within CTCs, with tumor-initiating properties able to self-renew and develop distant metastases (Reya et al., 2001) . For CTCs, to be biologically relevant, metastasis-initiation properties would have to be assumed.
In the past years, different subpopulations of melanoma cells with stem cell properties have been identified (Fang et al., 2005; Schatton et al., 2008; Boiko et al., 2010) . Such a kind of subpopulation was capable of proliferation, selfrenewal and they possessed exclusive or higher tumorigenicity in vivo compared with melanoma cell fractions devoid of stem cells markers. Different molecular markers have been identified for melanoma-initiating cells. Monzani et al., (2007) showed that both fresh tumor biopsies and continuous melanoma cell lines contain CD133 and ABCG2-positive cells with enhanced tumorigenic properties. Along with the development from banal nevi to primary melanomas to metastatic melanoma lesions, increasing expression of CD133 has been observed by immunohistochemistry (Klein et al., 2007) . CD133 is also a putative marker for several other cancer stem cells (Wright et al., 2008; Beier et al., 2007; Yin et al., 2007; Haraguchi et al., 2008) .
Nestin (NES) has been described in context of stem celllike subpopulations in melanoma cell lines (Grichnik et al., 2006) . Its expression has been associated with de-differentiation and more aggressive behaviour of the malignancy, and like CD133, is increasing during the development of invasive melanoma from banal nevi (Klein et al., 2007) . Although colocalization with the pre-melanosomal markers was noted, NES-positive cells were usually negative or slightly positive for gp100 (Grichnik et al., 2006) .
In a recent study, we investigated nestin expression at mRNA level in peripheral blood of melanoma patients (Fusi et al., 2010) . In the actual study, we evaluated the presence of melanoma cells bearing the stem cell-associated markers NES and CD133 in the bloodstream of patients with metastatic cutaneous and uveal melanomas.
RESULTS

Spiking experiments
In the assays, we added 0, 10, 50, 100, 500, and 700 cells of the cell line SK-Mel28, which expressed Melan-A (MLANA) and human melanoma black (HMB)-45, to 5 ml peripheral blood from healthy volunteers. After CD45 depletion, remaining cells were stained with anti-MLANA and anti-HMB-45 and were analyzed by flow cytometry. The assay was repeated five times to validate the reproducibility of the method and results were presented in Figure 1 . Analyses demonstrated the specificity of the assay (no positive signal for MLANA and HMB-45 when 0 cells were spiked) and its reproducibility. Average recovery rate was 74% with a range from 60 to 81% according to the number of cells spiked, with somewhat higher recovery rates when lower number of cells was spiked, within the range of error for spike-in dilutions at the lowest concentration. The process was linear for the tested concentrations (R 2 ¼ 0.9996; Po0.001; Figure 1 ).
Patients
In all, 20 ml blood anticoagulated with heparin were collected after informed consent from 32 consecutive patients affected by metastatic uveal (n ¼ 15) or cutaneous (n ¼ 17) melanomas, receiving various forms of systemic or intrahepatic chemotherapy at the Charité, Berlin, Germany and from 5 healthy volunteers according to ethically approved protocols. Patients' characteristics are listed in Table 1 .
Levels of CMCs
MLANA and/or HMB-45-positive cells were detected in 28 samples from 32 patients (87.5%; Table 1 ). Median count of In all, 0, 10, 50, 100, 500, and 700 cells of the cell line SK-Mel28 were spiked in 5 ml blood of healthy volunteers. After CD45 depletion, the remaining material was stained with antibodies against MLANA and HMB-45 and was analyzed by flow cytometry. The average of the data points is represented by horizontal bars. A best-fit line is graphed.
CMCs for the 32 patients was 53 cells per 10 ml blood (range: 0-1233 cells per 10 ml blood). Median level of CMCs was significantly higher in patients with high plasmatic levels of lactate dehydrogenase (LDH) (P ¼ 0.017; Figure 2a , left panel), but did not significantly differ among patients according to number of metastatic sites (P ¼ 0.12; Figure 2a , middle panel) and between high versus low tumor burden populations (P ¼ 0.065; Figure 2a , right panel). However, a trend to higher amount of CMCs was observed in patients with high tumor burden and increasing number of metastatic sites. No difference in CMC levels was observed when gender, primary tumor site, and AJCC (American Joint Committee on Cancer) stage in case of cutaneous melanoma, or only liver versus other sites±liver metastatic pattern in case of uveal melanoma were considered for analysis (data not shown).
Levels of CD133-positive CMCs
In 20 (71%) patients, the fraction of CD133-positive CMCs was o1% and CMCs were negative for expression of CD133 in 13 (46%) patients. All cells positive for CD133 were also positive for NES. For these reasons, we did not analyze double-positive cells separately.
CD133 was expressed within the MLANA-and/or HMB-45-positive subset, with a median percentage of 0.1% (0-23.4%). Median percentages of CD133-positive CMCs did not significantly differ between patients with normal versus high plasmatic levels of LDH (P ¼ 0.71; Figure 2b , left panel), among patients with different number of metastatic sites (P ¼ 0.43; Figure 2b , middle panel), and between high versus low tumor burden populations (P ¼ 0.40; Figure 2b , right panel). No difference in CD133-positive CMC percentages was observed when gender, primary tumor site, chemotherapy regimen, and AJCC stage in case of cutaneous melanoma or only liver versus other sites±liver metastatic pattern in case of uveal melanoma were considered for analysis (data not shown).
Levels of NES-positive CMCs
NES was expressed in the MLANA-and/or HMB-45-positive subset, with a median percentage of 18% (0-85.1%). Only one sample resulted to be negative for expression of NES. The median percentage of NES-positive CMCs was significantly higher in patients with high plasmatic levels of LDH (P ¼ 0.041; Figure 2c , left panel) and with high tumor burden (P ¼ 0.031; Figure 2c , right panel) and was significantly different among patients with different number of metastatic sites (P ¼ 0.019; Figure 2c , middle panel). The percentage of NES-positive CMCs did not correlate with absolute number of CMC (P ¼ 0.878). No difference in NES-positive CMC percentages was observed when gender, primary tumor site, chemotherapy regimen, and AJCC stage in case of cutaneous melanoma or only liver versus other sites ± liver metastatic pattern in case of uveal melanoma were considered for analysis (data not shown).
Prognostic impact on overall survival
The presence of CMCs as well as positivity of CMCs for CD133 were not associated with overall survival (data not shown). As NES was found to be expressed in all the samples except for one, in order to examine the prognostic implications of level of NES-expressing CMCs, we used the cutoff selected by the maxstat package of R, i.e. 35%. The cutoff identified eight patients with a percentage of NESpositive CMCs X35% and 20 patients with NES expression below the cutoff. A significant reduction in survival time was observed when the percentage of NES-expressing CMCs was equal or 435% (P ¼ 0.001; Figure 3 ). Cox regression analyses confirmed results presented above and revealed levels of LDH, percentage level of NES-positive CMCs, number of metastatic sites, and tumor burden to be strong prognostic factors (Table 2) .
Stem cell markers' expression on CMCs and in matched tissues
We next compared CD133 and NES expression levels on CMCs with those in metastatic tissue lesions from six patients with accessible metastases. We found similar expression profiles for CMCs and metastases. Furthermore, in this small series of patients, higher percentage levels of NES-positive CMCs in blood corresponded to metastatic tissue specimen with higher mitotic rate (i.e. elevated Ki-67 rates). Results are presented in Table 3 .
DISCUSSION
Detection of CTCs has been mainly performed by means of immunomagnetic positive cell selection methods for enriching CTC populations followed by flow cytometry or immunohistochemistry for visualization and quantification. Up to now, a method for detection of CMCs has not been validated because of the lack of a suitable clearly defined and continuously expressed surface marker.
In our study, we decided not to use a positive tumor cell selection protocol, as it would have required sufficient cellsurface expression of the chosen target molecule on all CMCs in order to investigate their full variety. We therefore employed a negative enrichment protocol based on efficient removal of CD45-positive leukocytes by ferromagnetic bead sorting and characterized the remaining small cell fraction. Spiking experiments demonstrated the specificity of the assay we employed, as no positive signal for MLANA or HMB-45 was observed within the CD45-negative fraction when 0 cells were spiked. In addition, detection rates were consistent with the ones reported for reverse transcriptase PCR analyses in AJCC stage IV melanoma patients (Keilholz et al., 2004) . We found a correlation between CMC count and level of LDH, whereas no further correlations with other prognostic factors or overall survival were observed. Indeed, the study was not designed to address this issue. Sampling of blood from patients was in fact performed randomly and CTC count was compared with parameters derived from the closest reevaluation, which should closely reflect the clinical situation CTCs represent a potential alternative to invasive biopsy. A major advantage of using immunomagnetic enrichment selection is, in fact, that the method allows detailed characterisation with respect to the phenotypic and genotypic properties of the CTCs and, as melanoma therapies may become more individualized, the assay may be informative to identify patients who could benefit from a specific therapy (Kitago et al., 2009 ). Furthermore, the development of therapies specifically targeting cancer-initiating cells may be of great benefit for patients with CTCs bearing stem cell properties. Using flow cytometric sorting protocols based on the expression of surface markers, putative tumor-initiating cells have been isolated from solid tumors, including melanoma. Tumor-initiating cells are operationally defined as a clinical tumor specimen identifiable by a molecular marker or marker combination, which, unlike cancer bulk populations negative for the particular markers, can initiate tumor formation and growth in hosts in vivo. Although most cancer stem cell studies has suggested that only a small subpopulation of tumor cells have tumorigenic potential, it has recently been shown that cancer-initiating cells do not necessarily have to be rare (Kelly et al., 2007; Kennedy et al., 2007) . Quintana et al. (2008) showed that modifications to xenotransplantation assay can dramatically increase the frequency of melanoma-initiating cells up to 27% of unsorted cells and Roesch et al. (2010) questioned the stem cell model itself, with a melanoma stem cell at the top of the tumor differentiation pyramid. Melanoma-initiating cells might be indeed tumor cells that can transiently acquire stemness properties depending on exogenous factors. All cancer stem cell studies have addressed the potential of a tumor-initiating cell to proliferate extensively and to form a tumor in hosts, not their actual fate in patients. It is therefore possible that cancer cell tumorigenic in mice might not correspond to tumorigenic cells in human patients. As metastases require the occurrence of tumor-initiating cells to arise, tumorinitiating cells should circulate in blood. CTCs may therefore be an ideal compartment where cancer-initiating cells should be looked for in cancer patients avoiding invasive biopsies. To address this point, in this study, we characterized melanoma cells circulating in blood from patients with metastatic melanoma for expression of stem cell-related markers. Markers such as NES (Grichnik et al., 2006) , ABCB5 (Schatton et al., 2008) , CD133 (Monzani et al., 2007) , CD20 (Fang et al., 2005) , and CD271 (Boiko et al., 2010) have been identified as to be possible candidates for the identification of melanoma-initiating cells. CD133 and NES were also wellestablished markers of central nervous system tumor cells and their overexpression has been correlated to poorer outcome (reviewed in Singh et al., 2007) . As central nervous system tumor and melanoma share the same embryological neuroectodermal origin, we decided to characterize CMCs for the expression of NES and CD133. CD133 was expressed to a lesser extent than NES on CMCs, with most of the samples showing an expression o1%. CD133 was expressed in all the tissue samples we analyzed and its expression was lower than NES in all the specimens examined. These results are consistent with published data from Klein et al. who identified NES expression in 69 of 80 metastatic melanoma lesions whereas CD133 expression was observed only in 39 of 84 metastatic melanomas. An increasing percentage of melanomas containing cells expressing CD133 or NES was observed when comparing primary and metastatic melanoma, but only NES showed a statistically significant difference (Klein et al., 2007) . A stepwise increase in NES expression was also described from banal nevi to primary melanomas to metastatic melanoma lesions indicating a potential role of NES expression for a more aggressive behavior (Flørenes et al., 1994; Ehrmann et al., 2005; Klein et al., 2007; Mihic-Probst et al., 2007) . Furthermore, we have recently showed that reverse transcriptase PCR detection of nestin transcripts in peripheral blood of patients with melanoma more closely reflected patient tumor burden than the melanocyte markers tyrosinase and MLANA, suggesting that higher expression of nestin transcripts might be associated with a more advanced disease (Fusi et al., 2010) . A correlation between NES expression and aggressiveness of the tumor might also be gathered from the fact that, in our small series of tissue specimens with matching blood samples, higher mitotic rate was in correspondence with higher fraction of NES-expressing CMCs.
Assuming that metastasis requires a dissemination of tumor cells with tumor-initiating properties, it might be possible to detect these cells among CTCs. According to this hypothesis, presence of circulating cancer-initiating cells should be associated with worse patient outcome.
In our present study, expression of NES on CMCs correlated with other known unfavourable prognostic factors supporting the hypothesis of NES expression in more aggressive melanomas. Furthermore, NES might be a prognostic factor when NESpositive cells are a relevant fraction of the whole CMC pool. CD133 did not correlate with known unfavourable prognostic factors, neither its expression was associated with a shorter overall survival. These findings are consistent with recently published results of Piras et al. Immunohistochemical stainings for NES and CD133 in 130 primary melanoma tumors and 32 nodal metastasis biopsy revealed NES to be a predictor of poor survival, whereas CD133 staining was not associated with survival (Piras et al., 2010) .
In order to verify a potential prognostic value of NES expression, however, an analysis of a large and homogenous patient cohort including stage II and III patients with sufficient follow-up would be necessary.
MATERIALS AND METHODS
Spiking experiments
For assessing reproducibility of the assay, serial dilutions of SK-Mel28 melanoma cells in 5 ml blood obtained from the healthy volunteers were performed. The human melanoma cell line SK-Mel28 was obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany) and grown in RMPI 1640 (Biochrom AG, Berlin, Germany) supplemented with 10% fetal bovine serum, 2% L-glutamine, and 1% of a stock solution of penicillin/ streptomicin.
Melanoma cells' enrichment and flow cytometry analysis
Blood samples were processed within 2 hours of collection. Briefly, peripheral blood mononuclear cells were prepared by Ficoll-Plaque Plus (GE Healthcare Bio-Sciences, Uppsala, Sweden) density gradient centrifugation. After washing peripheral blood mononuclear cells three times with sterile phosphate-buffered saline, cells were enriched for tumor cells by CD45 depletion of the leukocyte fraction using a magnetic bead separation technique (EasySep, Stem Cells Technologies, Vancouver, BC, Canada) following manufacturer's instructions with minor modifications. The remaining material was split in two fractions. Potential CMCs were identified using flow cytometry with the markers MLANA (mouse monoclonal, clone A103, Dako, Glostrup, Denmark) and HMB-45 (mouse monoclonal, Dako). FITC goat anti-mouse IgG1 (Dako) was used as secondary antibody. Multiparameter cytometry was carried out to co-stain with NES phycoerythrin-labeled (mouse monoclonal, clone 307501, product number IC1259P, R&D System, Minneapolis, MN) and CD133 allophycocyanin-labeled (mouse monoclonal, clone 293C3, product number 130-090-826, Miltenyi Biotec, Bergisch Gladbach, Germany). Antibody batches were titrated to determine the optimal dosage. Control tubes included isotypic controls purchased from the same manufacturer. Cells were permeabilized for intracellular staining. Briefly, pellet was resuspended in 2 ml of a sterile solution containing 0.1% saponin, 0.05% NaN 3 in Hanks' Balanced Salt Solution (Shrimp alkaline phosphatase buffer). Cells were centrifuged at 200 Â g for 7 minutes; supernatant decanted, ensuring that B200 ml of Shrimp alkaline phosphatase buffer remained in the tube. Cells were subsequently stained and incubated for 45 minutes in the dark at room temperature. Before analysis, cells were resuspended in 500 ml phosphate-buffered saline. Cells were acquired on a FACSCalibur system (BD Biosciences, San José, CA) and entire 500 ml was evaluated. Data were analyzed using FlowJo 7.2.5 software (Tree Star, Ashland, OR). Absolute melanoma cell number was expressed as counted cells positive for the melanocyte markers per 10 ml blood. Results were expressed as the percentage of CD133 or NES-positive cells among circulating melanoma (MLANA and/or HMB-45) cells.
Immunohistochemistry
For immunohistochemistry, 2-3 mm sections of formalin-fixed and paraffin-embedded tissue were cut, deparaffinized by xylene, Circulating Melanoma Cells Express Stem Cell Markers rehydrated through a series of graded ethanols, and subjected to a heat-induced epitope-retrieval step before incubation with antibodies. Sections for NES were immersed in sodium citrate buffer solution at pH 6.0, sections for CD133 were immersed in EDTA buffer at pH 8.0, and both were heated in a high-pressure cooker for 2 minutes and 1 minute, respectively. Slides were rinsed in cool running water, washed in Tris-buffered saline (pH 7.4) and incubated with primary antibodies each for 30 minutes. The primary antibodies included monoclonal anti-human antibody against NES (dilution 1:1,000; R&D Systems) and the monoclonal anti-human CD133 antibody (dilution 1:100; Miltenyi Biotec). For detection, the strepta-vidinAP kit (K5005, Dako) was used. The expressions of NES and CD133 were confined to the plasma membrane and cytoplasm.
Statistics
Results were expressed as medians and range. As data did not pass the Kolmogorov-Smirnov test for normal distribution, nonparametric Mann-Whitney U-test and Kruskal-Wallis test were used, where appropriate. Correlations were assessed with the use of the Pearson's correlation coefficient or with Spearman's rank correlation coefficient, where appropriate. NES expression level on CMCs was dichotomized using the Maxstat package of R in order to determine the cutoff that best discriminated between different groups of patients for overall survival. In order to define the cut point that provides the best separation into two groups, Maxstat computes the maximally selected log-rank statistic for cut points between the 10 and 90% quantile of the mean expression following the method of Hothorn and Lausen (2003) . Overall survival was calculated from the time of inclusion in the study until death. Survival curves were plotted by Kaplan-Meier method and were compared using log-rank test. Cox proportional hazard regression was used to determine the prognostic value of count of cells, percentage of CD133-positive CMCs, and percentage of NES-positive CMCs. Variables included in the analysis were LDH levels (o247 U l À1 vs X247 U l À1 ), tumor burden (high vs low), and number of metastatic sites (0-1 vs 2 vs 42). A P-valuep0.05 was considered as statistically significant. Because of multiple testing, all P-values should be regarded as exploratory, requiring validation in a separate patient cohort. Data were analyzed using SPSS software (SPSS, Chicago, IL) and R v. 2.6.0 software (www.r-project.org/).
